|
Market Closed -
Swiss Exchange
12:30:07 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 8.840 CHF | -1.56% |
|
+4.00% | -62.94% |
| 10-22 | Newron Pharmaceuticals S.p.A. Completes Enrollment In Pivotal Phase 3 ENIGMA-TRS 1 Study | CI |
| 10-22 | Newron Pharmaceuticals Completes Enrollment for Schizophrenia Drug Late-stage Trial | MT |
Company Valuation: Newron Pharmaceuticals S.p.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27.93 | 27.99 | 94.91 | 185.1 | 511.9 | 203.1 | - | - |
| Change | - | 0.21% | 239.07% | 94.99% | 176.62% | -60.33% | - | - |
| Enterprise Value (EV) 1 | 27.93 | 60.23 | 114.7 | 225.7 | 521.2 | 217.3 | 221.2 | 203.1 |
| Change | - | 115.64% | 90.45% | 96.77% | 130.92% | -58.31% | 1.81% | -8.2% |
| P/E | -1.86x | -1.6x | -5.84x | 11.2x | -38.9x | -6.06x | 16.1x | 7.65x |
| PBR | - | -2x | -3.17x | 130x | -46x | -18.4x | - | - |
| PEG | - | -0.1x | 0.82x | -0x | 0x | -0x | -0x | 0x |
| Capitalization / Revenue | 4.85x | 4.59x | 10.5x | 3.6x | 26.8x | 24.4x | 3.51x | 2.94x |
| EV / Revenue | 4.85x | 9.88x | 12.7x | 4.39x | 27.3x | 26.1x | 3.82x | 2.94x |
| EV / EBITDA | -2.3x | -4.6x | -10x | 8.56x | -115x | -7.05x | 3.29x | 4.32x |
| EV / EBIT | -2.26x | -4.53x | -9.86x | 8.62x | -111x | -6.81x | 9.09x | 4.32x |
| EV / FCF | - | -5.42x | -11.3x | -12.8x | 16.1x | -7.49x | 1.61x | 3.76x |
| FCF Yield | - | -18.4% | -8.85% | -7.81% | 6.2% | -13.3% | 61.9% | 26.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.84 | -0.98 | -0.91 | 0.85 | -0.66 | -1.578 | 0.5925 | 1.25 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.762 | 6.094 | 9.057 | 51.39 | 19.13 | 8.322 | 57.9 | 69 |
| EBITDA 1 | -12.15 | -13.1 | -11.43 | 26.36 | -4.525 | -30.81 | 67.16 | 47 |
| EBIT 1 | -12.36 | -13.3 | -11.63 | 26.17 | -4.697 | -31.92 | 24.33 | 47 |
| Net income 1 | -14.9 | -17.49 | -16.22 | 15.84 | -13.24 | -32.8 | 9.391 | 27 |
| Net Debt 1 | - | 32.24 | 19.8 | 40.64 | 9.287 | 14.21 | 18.13 | - |
| Reference price 2 | 1.565 | 1.568 | 5.318 | 9.510 | 25.645 | 9.561 | 9.561 | 9.561 |
| Nbr of stocks (in thousands) | 17,845 | 17,845 | 17,845 | 19,459 | 19,961 | 21,239 | - | - |
| Announcement Date | 3/15/22 | 3/14/23 | 3/19/24 | 3/31/25 | 3/23/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.16x | 26.53x | -7.16x | - | 226M | |
| 17.08x | 6.33x | 12.4x | 1.75% | 64.14B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 55.53B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.03B | |
| 35.05x | 3.37x | 14.55x | -.--% | 45.99B | |
| 48.28x | 5.55x | 30.42x | -.--% | 42.45B | |
| -19.33x | 186.93x | -20.57x | -.--% | 40.45B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.25B | |
| 36.51x | 6.64x | 22.27x | -.--% | 34.47B | |
| 26.96x | 5.67x | 14.71x | -.--% | 24.23B | |
| Average | 23.57x | 26.35x | 13.29x | 0.34% | 39.28B | |
| Weighted average by Cap. | 26.72x | 24.89x | 15.79x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NWRN Stock
- Valuation Newron Pharmaceuticals S.p.A.
Select your edition
All financial news and data tailored to specific country editions
